myCOPD for self-management of chronic obstructive pulmonary disease (MIB214)
NICE has developed a medtech innovation briefing (MIB) on myCOPD for self-management of chronic obstructive pulmonary disease
Search results
273 results
-
-
COVID-19 rapid evidence summary: angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in people with or at risk of COVID-19 (ES24)
ES24 Key messages The content of this evidence review was up-to-date on
-
COVID 19 rapid evidence summary: Anakinra for COVID-19 associated secondary haemophagocytic lymphohistiocytosis (ES26)
ES26 Key messages The content of this evidence review was up-to-date on 13 May 2020. See summaries of product characteristics (SPCs)
-
COVID-19 rapid evidence summary: Long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19 (ES25)
ES25 Key messages The content of this evidence review was up-to-date on 20 April 2020. See summaries of product characteristics
-
COVID-19 rapid evidence summary: acute use of non-steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19 (ES23)
COVID-19 rapid evidence summary: acute use of non-steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19
-
Antimicrobial prescribing: meropenem with vaborbactam (ES21)
Summary of the evidence on antimicrobial prescribing of meropenem with vaborbactam (Vaborem) to inform local NHS planning and decision making
-
Antimicrobial prescribing: ceftolozane with tazobactam for treating hospital-acquired pneumonia, including ventilator-associated pneumonia (ES22)
Summary of the evidence on the antimicrobial prescribing of ceftolozane with tazobactam for hospital-acquired pneumonia, including ventilator-associated
-
Acute kidney injury (AKI): use of medicines in people with or at increased risk of AKI (KTT17)
This document summarises the evidence base on the use of medicines in people with or at increased risk of acute kidney injury . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .
-
Anticoagulants, including direct-acting oral anticoagulants (DOACs) (KTT16)
This key therapeutic topic has been reincluded in the September 2019 update of medicines optimisation: key therapeutic topics. This document summarises the evidence base on anticoagulants , including direct-acting oral anticoagulants (DOACs). It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .
-
Wound care products (KTT14)
This document summarises the evidence base on wound care products . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .
-
Type 2 diabetes mellitus: medicines optimisation priorities (KTT12)
This document summarises the evidence base on type 2 diabetes mellitus: medicines optimisation priorities . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .
-
Antimicrobial stewardship: prescribing antibiotics (KTT9)
This document summarises the evidence base on antimicrobial stewardship: prescribing antibiotics . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .
-
Antipsychotics in people living with dementia (KTT7)
This document summarises the evidence base on antipsychotics in people living with dementia . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .
-
Hypnotics (KTT6)
This document summarises the evidence base on hypnotics . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .
-
Asthma: medicines safety priorities (KTT5)
This document summarises the evidence base on asthma: medicines safety priorities . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .
-
Lipid-modifying drugs (KTT3)
This key therapeutic topic has been reincluded in the September 2019 update of medicines optimisation: key therapeutic topics. This document summarises the evidence base on lipid-modifying drugs. It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .
-
Suicide prevention: optimising medicines and reducing access to medicines as a means of suicide (KTT24)
This document summarises the evidence base on suicide prevention: optimising medicines and reducing access to medicines as a means of suicide . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .
-
Shared decision making (KTT23)
This document summarises the evidence base on shared decision making . It is a key therapeutic topic that has been identified to support Medicines Optimisation. It is not formal NICE guidance .
-
Chemotherapy dose standardisation (KTT22)
This document summarises the evidence base on chemotherapy dose standardisation . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .
-
Medicines optimisation in chronic pain (KTT21)
This document summarises the evidence base on medicines optimisation in chronic pain . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .
-
Safer insulin prescribing (KTT20)
This document summarises the evidence base on safer insulin prescribing . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .
-
Psychotropic medicines in people with learning disabilities whose behaviour challenges (KTT19)
This document summarises the evidence base on psychotropic medicines in people with learning disabilities whose behaviour challenges . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .
-
Multimorbidity and polypharmacy (KTT18)
This document summarises the evidence base on multimorbidity and polypharmacy . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .
-
COVID-19 rapid evidence summary: vitamin D for COVID-19 (ES28)
ES28 Key messages The content of this evidence summary was up-to-date on 18 June 2020. See summaries of product characteristics
-
COVID 19 rapid evidence summary: Remdesivir for treating hospitalised patients with suspected or confirmed COVID-19 (ES27)
ES27 Key messages The content of this evidence review was up-to-date on 4 June 2020. See summaries of product characteristics
-
Cytokine adsorption devices for treating respiratory failure in people with COVID-19 (MIB217)
NICE has developed a medtech innovation briefing (MIB) on cytokine adsorption devices for treating respiratory failure in people with COVID-19
-
Cor-Knot for tying suture knots in valve surgery (MIB206)
NICE has developed a medtech innovation briefing (MIB) on Cor-Knot for tying suture knots in valve surgery
-
Artificial intelligence for analysing CT brain scans (MIB207)
NICE has developed a medtech innovation briefing (MIB) on artificial intelligence for analysing CT brain scans
-
NATROX oxygen wound therapy for managing diabetic foot ulcers and complex or chronic non-healing wounds (MIB208)
NICE has developed a medtech innovation briefing (MIB) on NATROX oxygen wound therapy for managing diabetic foot ulcers and complex or chronic non-healing wound
-
EarlyCDT-Lung for cancer risk classification of indeterminate pulmonary nodules (MIB209)
NICE has developed a medtech innovation briefing (MIB) on EarlyCDT-Lung for cancer risk classification of indeterminate pulmonary nodules
-
Leukomed Sorbact for preventing surgical site infection (MIB197)
Advice on the use of Leukomed Sorbact for preventing surgical site infection (SSI) to aid local decision making
-
AmnioSense for unexplained vaginal wetness in pregnancy (MIB198)
Advice on the use of AmnioSense (non-invasive diagnostic pad/liner) for unexplained vaginal wetness in pregnancy to aid local decision making
-
Optowire for measuring fractional flow reserve (MIB199)
Advice on the use of Optowire (sterile, fibreoptic-based, disposable guide wire) for measuring fractional flow reserve (FFR) to aid local decision making
-
PIUR tUS for abdominal aortic aneurysm surveillance and endovascular aneurysm repair endoleak detection (MIB200)
Advice on the use of PIUR tUS for abdominal aortic aneurysm surveillance and endovascular aneurysm repair endoleak detection to aid local decision making
-
eXroid for internal haemorrhoids (MIB201)
Advice on the use of eXroid, using direct current electrotherapy to blood vessels of internal haemorrhoid to shrink haemorrhoids, to aid local decision making
-
LQD Spray for treating acute and chronic wounds (MIB202)
Advice on the use of LQD Spray (spray-on dressing containing modified biopolymer chitosan FH02) for treating acute/chronic wounds to aid local decision making
-
PulmoVista 500 for monitoring ventilation in critical care (MIB203)
Advice on the use of PulmoVista 500 for monitoring ventilation in critical care to aid local decision making
-
Plus Sutures for preventing surgical site infection (MIB204)
NICE has developed a medtech innovation briefing (MIB) on Plus Sutures for preventing surgical site infection
-
National Early Warning Score systems that alert to deteriorating adult patients in hospital (MIB205)
NICE has developed a medtech innovation briefing (MIB) on National Early Warning Score systems that alert to deteriorating adult patients in hospital
-
TUC Safety Valve to prevent balloon inflation in the urethra during transurethral catheterisation (MIB210)
NICE has developed a medtech innovation briefing (MIB) on TUC Safety Valve to prevent balloon inflation in the urethra during transurethral catheterisation
-
Lifelight First for monitoring vital signs (MIB213)
NICE has developed a medtech innovation briefing (MIB) on Lifelight First for monitoring vital signs
-
Space from Depression for treating adults with depression (MIB215)
NICE has developed an Improving Access to Psychological Therapies (IAPT) report on Space from Depression for treating adults with depression
-
SuperNO2VA for the relief of upper airway obstruction in people with obstructive sleep apnoea (MIB190)
Advice on the use of SuperNO2VA for the relief of upper airway obstruction in people with obstructive sleep apnoea to aid local decision making
-
UroShield for preventing catheter-associated urinary tract infections (MIB191)
Advice on the use of UroShield for preventing catheter-associated urinary tract infections (CAUTI) to aid local decision making
-
InterDry for intertrigo (MIB192)
Advice on the use of InterDry for intertrigo (inflammatory skin rash) to aid local decision making
-
Alpha-Stim AID for anxiety (MIB193)
Advice on the use of Alpha-Stim AID for anxiety to aid local decision making
-
superDimension Navigation System to help diagnostic sampling of peripheral lung lesions (MIB194)
Advice on the use of superDimension Navigation System to help diagnostic sampling of peripheral lung lesions to aid local decision making
-
MR-proADM test for use with clinical deterioration scores in cases of suspected infection (MIB195)
Advice on the use of MR-proADM test for use with clinical deterioration scores in cases of suspected infection to aid local decision making
-
DyeVert for reducing contrast media in coronary and peripheral angiography (MIB196)
NICE has developed a medtech innovation briefing (MIB) on DyeVert for reducing contrast media in coronary and peripheral angiography
-
HemaClear for bloodless surgical field during limb surgery (MIB187)
Advice on the use of HemaClear for bloodless surgical field during limb surgery to aid local decision making